Ronald Shazer

1.1k total citations
25 papers, 570 citations indexed

About

Ronald Shazer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ronald Shazer has authored 25 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Ronald Shazer's work include Cancer Immunotherapy and Biomarkers (5 papers), Prostate Cancer Treatment and Research (4 papers) and Renal cell carcinoma treatment (3 papers). Ronald Shazer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Prostate Cancer Treatment and Research (4 papers) and Renal cell carcinoma treatment (3 papers). Ronald Shazer collaborates with scholars based in United States, Spain and Canada. Ronald Shazer's co-authors include Dawei Xuan, Michael Amantea, Joanna C. Masters, Dana J. Nickens, Mitchell E. Gross, David B. Agus, Steven Tucker, Tanya B. Dorff, Patricia LoRusso and Hossein Borghaei and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hepatology.

In The Last Decade

Ronald Shazer

25 papers receiving 552 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ronald Shazer United States	12	349	170	164	150	56	25	570
E G Wright United Kingdom	11	258 0.7×	232 1.4×	303 1.8×	120 0.8×	75 1.3×	20	688
Dhara MacDermed United States	12	269 0.8×	102 0.6×	288 1.8×	220 1.5×	108 1.9×	17	722
U Ferrando Italy	8	321 0.9×	55 0.3×	321 2.0×	213 1.4×	53 0.9×	24	630
Kaori Fujimoto-Ouchi United States	15	552 1.6×	241 1.4×	242 1.5×	283 1.9×	54 1.0×	28	823
P. Mukhopadhyay United States	9	463 1.3×	36 0.2×	47 0.3×	136 0.9×	10 0.2×	27	658
A. Lambiase Italy	17	613 1.8×	146 0.9×	297 1.8×	181 1.2×	102 1.8×	55	899
Lida Pacaud United States	12	520 1.5×	84 0.5×	245 1.5×	111 0.7×	84 1.5×	56	621
W. H. Miller United States	9	486 1.4×	104 0.6×	283 1.7×	166 1.1×	100 1.8×	17	723
Elena Bonazzoli United States	15	319 0.9×	122 0.7×	147 0.9×	99 0.7×	76 1.4×	31	531

Countries citing papers authored by Ronald Shazer

Since Specialization

Citations

This map shows the geographic impact of Ronald Shazer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Shazer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Shazer more than expected).

Fields of papers citing papers by Ronald Shazer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Shazer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Shazer. The network helps show where Ronald Shazer may publish in the future.

Co-authorship network of co-authors of Ronald Shazer

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Shazer. A scholar is included among the top collaborators of Ronald Shazer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Shazer. Ronald Shazer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jänne, Pasi A., Jason T. Henry, K. Papadopoulos, et al.. (2024). 503LBA LBA Orals: Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del). European Journal of Cancer. 211. 114981–114981. 2 indexed citations

Borghaei, Hossein, Melissa L. Johnson, Edward B. Garon, et al.. (2023). LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S1308–S1308. 4 indexed citations

He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations

Leal, Ticiana, David Berz, Igor I. Rybkin, et al.. (2022). 43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy. Annals of Oncology. 33. S19–S20. 13 indexed citations

Leal, Ticiana, David Berz, Igor I. Rybkin, et al.. (2021). 1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy. Annals of Oncology. 32. S949–S949. 15 indexed citations

Msaouel, Pavlos, Arlene O. Siefker‐Radtke, Randy F. Sweis, et al.. (2020). 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). Annals of Oncology. 31. S556–S556. 6 indexed citations

Percent, Ivor, Craig H. Reynolds, Kartik Konduri, et al.. (2020). Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).. Journal of Clinical Oncology. 38(15_suppl). TPS9635–TPS9635. 12 indexed citations

Luo, Wen, et al.. (2018). Improved Survival with Enzastaurin Treatment in Diffuse Large B-Cell Lymphoma Patients with the Novel Genetic Biomarker, DGM1. Blood. 132(Supplement 1). 4207–4207. 3 indexed citations

Masters, Joanna C., Dana J. Nickens, Dawei Xuan, Ronald Shazer, & Michael Amantea. (2017). Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Investigational New Drugs. 36(1). 121–135. 219 indexed citations

10.

Shapiro, Geoffrey I., Ulka N. Vaishampayan, Patricia LoRusso, et al.. (2017). First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Investigational New Drugs. 35(3). 315–323. 32 indexed citations

11.

Choueiri, Toni K., Neeraj Agarwal, Thai H. Ho, et al.. (2016). TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC). Annals of Oncology. 27. vi295–vi295. 3 indexed citations

12.

Choueiri, Toni K., M. Dror Michaelson, Edwin M. Posadas, et al.. (2016). A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). Annals of Oncology. 27. vi280–vi280. 5 indexed citations

13.

Ahluwalia, Manmeet S., Lisa R. Rogers, Rekha Chaudhary, et al.. (2016). A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma.. Journal of Clinical Oncology. 34(15_suppl). 2035–2035. 8 indexed citations

14.

Attia, Steven, Kamalesh K. Sankhala, Richard F. Riedel, et al.. (2016). A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology. 34(15_suppl). 11016–11016. 16 indexed citations

15.

Shapiro, Geoffrey I., Patricia LoRusso, Ulka N. Vaishampayan, et al.. (2015). First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). TPS2603–TPS2603. 8 indexed citations

16.

LoRusso, Patricia, B. Markman, Josep Tabernero, et al.. (2009). A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3502–3502. 32 indexed citations

17.

Dorff, Tanya B., et al.. (2007). Successful Treatment of Metastatic Androgen-Independent Prostate Carcinoma in a Transsexual Patient. Clinical Genitourinary Cancer. 5(5). 344–346. 46 indexed citations

18.

Shazer, Ronald, Anjali Jain, Anna Galkin, et al.. (2005). Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. British Journal of Urology. 97(4). 691–697. 37 indexed citations

19.

Gross, Mitchell E., Seong Jin Jo, Dan Huang, et al.. (2005). Obesity, ethnicity, and surgical outcomes for clinically localized prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 9615–9615. 1 indexed citations

20.

Gross, Mitchell E., Ronald Shazer, & David B. Agus. (2004). Targeting the HER-kinase axis in cancer. Seminars in Oncology. 31(1 Suppl 3). 9–20. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact